Equillium, Inc. (EQ) stock
EQNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.21+0.06 (+5.22%)
Close on Nov 17, 2026Market cap $76.72MP/E –Yield –
Equillium revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Equillium's revenue for the twelve months ending Dec 31, 2024 was $41.10M, up 13.9% year over year. For fiscal 2024 it was $41.10M, up 13.9% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $41.10M | +13.9% |
| FY2023 | Dec 31, 2023 | $36.08M | +129.0% |
| FY2022 | Dec 31, 2022 | $15.76M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | $4.39M | -52.3% |
| Q3 FY2024 | Sep 30, 2024 | $12.16M | +37.1% |
| Q2 FY2024 | Jun 30, 2024 | $13.85M | +51.8% |
| Q1 FY2024 | Mar 31, 2024 | $10.69M | +20.4% |
| Q4 FY2023 | Dec 31, 2023 | $9.21M | – |
| Q3 FY2023 | Sep 30, 2023 | $8.87M | – |
| Q2 FY2023 | Jun 30, 2023 | $9.12M | – |
| Q1 FY2023 | Mar 31, 2023 | $8.88M | – |
See a number that looks wrong?